Accelerated Clinical Trial AgreementAccelerated Clinical Trial Agreement • January 13th, 2020
{MONTH}, {YEAR} (the “Effective Date”) by and between {INSTITUTION NAME; DESCRIBE INSTITUTION}, a [e.g. non-profit, educational, research, healthcare] institution (“Institution”) with an address at
Accelerated Clinical Trial AgreementAccelerated Clinical Trial Agreement • January 21st, 2020 • BriaCell Therapeutics Corp. • Pharmaceutical preparations
This Accelerated Clinical Trial (ACTA) Agreement (“Agreement”) is made as of August 31, 2018 (“Effective Date”) by and between University of Miami (“Institution”), having an address at 1320 S. Dixie Highway, Suite 650, Coral Gables, FL 33146, and Cancer Insight, LLC, a limited liability company having its principal place of business at 1422 E Grayson, 3rd Floor, San Antonio, TX 78208 (“CRO”). CRO and Institution are herein referred to collectively as “Parties.” Individually, each of CRO and Institution is a “Party.”
Accelerated Clinical Trial AgreementAccelerated Clinical Trial Agreement • October 11th, 2016
{MONTH}, {YEAR} (the “Effective Date”) by and between {INSTITUTION NAME}, a non-profit, educational, research and healthcare institution (“Institution”) with an address at {INSTITUTION ADDRESS} and {COMPANY NAME}, a corporation having its principal place of business at {COMPANY ADDRESS}(“CRO”). CRO and Institution are herein referred to collectively as “Parties.” Individually, each of CRO and Institution is a “Party.”
Accelerated Clinical Trial AgreementAccelerated Clinical Trial Agreement • August 30th, 2019 • BriaCell Therapeutics Corp. • Pharmaceutical preparations
This Accelerated Clinical Trial (ACTA) Agreement (“Agreement”) is made as of September 12,2018 (“Effective Date”) by and between Providence Health & Services - Washington, dba Providence Regional Medical Center Everett (“Institution”), a non-profit corporation organized under the laws of the State of Washington, having an address at 1330 Rockefeller Avenue, Suite 440, Everett, Washington 98201, The Everett Clinic, PLLC, a Washington professional limited liability company with a place of business at 3901 Hoyt Avenue, Everett, WA 98201 (“Clinic”), Jason Lukas, M.D., an employee of Clinic, with a place of business at 1717 13th Street, Suite 300, Everett, Washington 98201 (“Principal Investigator”), and Cancer Insight, LLC, a limited liability company having its principal place of business at 1422 E Grayson, 3rd Floor, San Antonio, TX 78208 (“CRO”). CRO, Clinic, Principal Investigator, and Institution are herein referred to collectively as “Parties.” Individually, each of CRO, Clinic, Prin
Accelerated Clinical TrialAccelerated Clinical Trial Agreement • August 27th, 2015
CLICK HERE TO ENTER MONTH., CLICK HERE TO ENTER YEAR. (the “Effective Date”) by and between the University of Rochester, a non-profit,
Accelerated Clinical Trial AgreementAccelerated Clinical Trial Agreement • October 22nd, 2019 • BriaCell Therapeutics Corp. • Pharmaceutical preparations
This Accelerated Clinical Trial (ACTA) Agreement (“Agreement”) is made as of July 23, 2018 (“Effective Date”) by and between Thomas Jefferson University, a Pennsylvania non-profit corporation (“Institution”), having an address at 125 S. 9th Street, Second Floor Sheridan, Philadelphia, PA 19107, and Cancer Insight, LLC, a limited liability company having its principal place of business at 110 East Houston Street, Floor Seven, San Antonio, TX 78205 (“CRO”). CRO and Institution are herein referred to collectively as “Parties.” Individually, each of CRO and Institution is a “Party.”
